Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech

Steve Stiles

  • 1
    News

    Empagliflozin a winner in challenging arena of stabilized acute HF

    November 19, 2021

    Early in-hospital initiation of SGLT2 inhibitors “should be considered the new standard of care” in most patients with heart failure regardless of their ejection fraction, says an expert observer.

  • News

    ASNC rejects new chest pain guideline it helped create

    November 2, 2021

    “We believe that the document fails to provide unbiased guidance to health care professionals on the optimal evaluation of patients with chest pain.”

  • 1
    News

    New reports help nail down myocarditis risk with COVID-19 vaccine

    October 11, 2021

    Myocarditis linked to the two mRNA SARS-CoV-2 vaccines is rare, usually mild and self-limited, and a lot less likely than the usually more severe cases seen in COVID-19.

  • News

    Is AFib a stroke cause or innocent bystander? The debate continues

    October 5, 2021

    Many believe AFib is a risk marker for stroke, but new evidence suggests it may be a causal risk factor.

  • News

    DOACs best aspirin after ventricular ablation: STROKE-VT

    August 2, 2021

    Cerebrovascular protection was far better on DOACs after catheter ablation for VT or extrasystoles in the trial and may yet be further improved.

  • 1
    News

    ESC heart failure guideline to integrate bounty of new meds

    July 29, 2021

    It has a simple answer to a seemingly complex issue: how to merge the newly approved with mainstay drug therapies. And it conditionally okays meds in a group long without guideline-directed options.

  • News

    Are left atrial thrombi that defy preprocedure anticoagulation predictable?

    June 11, 2021

    Features that predispose to such persistent LA thrombi, which are not very rare, could potentially guide more targeted TEE screening before rhythm-control procedures.

  • 1
    News

    New light cast on type 2 MI aims to sharpen diagnosis, therapy

    February 23, 2021

    A large survey of type 2 MI, triggered when myocardial oxygen demand outstrips supply, points to confusion hindering its diagnosis and treatment and reveals the rarity of revascularization.

  • 1
    News

    FDA expands sacubitril/valsartan indication to embrace some HFpEF

    February 17, 2021

    The newly approved labeling for sacubitril/valsartan (Entresto) is simply for “chronic heart failure” but almost teasingly adds, “the benefits are most clearly evident” at below-normal LVEF.

  • 1
    News

    Myocarditis by CMR may be rare after COVID-19 in elite athletes

    January 27, 2021

    Some supposed ‘myocarditis’ detected by MRI after COVID-19 in university varsity competitors might be normal heart muscle – normal for athletes, that is, propose researchers.

1 2Next
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
fa-facebookfa-linkedinfa-instagramfa-youtube-playfa-commentfa-envelopefa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences